Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 3/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9489213 | 0.87 | ALDH1A1 (0.48) | DPP8DPP7DPP4OPRM1OPRD1 | |
| SCHEMBL9489209 | 0.87 | ALDH1A1 (0.48) | DPP8DPP7DPP4OPRM1OPRD1 | |
| SCHEMBL7610256 | 0.84 | ALDH1A1 (0.42) | DPP8DPP7DPP4FAPACE | |
| Hydrochloric Acid SCHEMBL3847558 | 0.83 | ALDH1A1 (0.42) | DPP8DPP7DPP4FAPACE | |
| SCHEMBL7267315 | 0.76 | DPP4 (0.43) | DPP8DPP4 | |
| SCHEMBL7777173 | 0.74 | DPP8 (0.48) | DPP8DPP7DPP4OPRM1OPRD1 | |
| SCHEMBL9490722 | 0.74 | DPP8 (0.54) | DPP8DPP7DPP4NTMT1DPP9 | |
| SCHEMBL7041303 | 0.70 | PREP (0.45) | DPP7DPP4F2 | |
| SCHEMBL4889705 | 0.69 | ALDH1A1 (0.55) | — | |
| SCHEMBL7413474 | 0.68 | DPP4 (0.47) | DPP8DPP7DPP4OPRM1DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121600-B2 | METHOD AND SUBSTANCES FOR DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS | BRAHMS AG (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-7998686-B2 | Method for determining sepsis using pro-BNP | B.R.A.H.M.S. GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-7972799-B2 | Method for determining sepsis using pro-ADM | B.R.A.H.M.S. GMBH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-20110008812-A1 | METHODS AND SUBSTANCES FOR THE DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS | B.R.A.H.M.S. GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2028493-B1 | Procalcitonin 3-116 | BRAHMS AG (DE) | 2010-07-28 | — | — | EP | disclosed |
| US-7723492-B2 | Method for the detection of sepsis using procalcitonin-3-116 | B.R.A.H.M.S. AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20090233311-A1 | METHODS AND SUBSTANCES FOR THE DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS | B.R.A.H.M.S. GMBH (DE) | 2009-09-17 | — | — | US | disclosed |
| US-20090215076-A1 | Methods and substances for the diagnosis and therapy of sepsis and sepsis-like systemic infections | B.R.A.H.M.S. GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090098571-A1 | METHODS AND SUBSTANCES FOR THE DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS | B.R.A.H.M.S. GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-7498139-B2 | Method for determining sepsis using pro-ANF | B.R.A.H.M.S. AKTIENGESELLSCHAFT (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1770397-A1 | Procalcitonin 3-116 | B.R.A.H.M.S. Aktiengesellschaft (DE) | 2007-04-04 | — | — | EP | disclosed |
| EP-1408334-B1 | Procalcitonin 3-116 | BRAHMS AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| EP-1121600-B1 | METHOD AND SUBSTANCES FOR DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS | BRAHMS AG (DE) | 2006-03-15 | — | — | EP | disclosed |
| US-20040180396-A1 | Method and substances for diagnosis and therapy of sepsis and sepsis-like systemic infections | B.R.A.H.M.S AKTIENGESELLSCHAFT (DE) | 2004-09-16 | — | — | US | disclosed |
| US-6756483-B1 | USING RECOMBINANT PROCALCITONIN IN THE DIAGNOSIS AND THERAPY OF SEPTIC DISEASES AND THE MEASUREMENT OF PROHORMONES OTHER THAN PROCALCITONIN, AND OF DIPEPTIDYL PEPTIDASE IV, AS BIOMARKERS IN THE DIAGNOSIS OF SEPSIS | B.R.A.H.M.S AKTIENGESELLSCHAFT (DE) | 2004-06-29 | — | — | US | disclosed |
| EP-1408334-A1 | Procalcitonin 3-116 | B.R.A.H.M.S. Aktiengesellschaft (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-0821689-B1 | TUMOR PROTEASE ACTIVATED PRODRUGS OF PHOSPHORAMIDE MUSTARD ANALOGS | DRUG INNOVATION & DESIGN INC (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-0821689-A1 | TUMOR PROTEASE ACTIVATED PRODRUGS OF PHOSPHORAMIDE MUSTARD ANALOGS | Drug Innovation & Design, Inc. (US) | 1998-02-04 | — | — | EP | disclosed |
| US-5659061-A | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities | DRUG INNOVATION & DESIGN, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1996033198-A1 | TUMOR PROTEASE ACTIVATED PRODRUGS OF PHOSPHORAMIDE MUSTARD ANALOGS | DRUG INNOVATION & DESIGN, INC. (US) | 1996-10-24 | — | — | WO | disclosed |